Merck KGaA to Acquire Silence Therapeutics for $1.3 Billion
The companies entered a definitive deal valuing Silence Therapeutics at about $1.3 billion in equity, or $20.00 per ADS. Closing is expected in Q1 2027, subject to shareholder, Court and regulatory approvals.
Silence Therapeutics has entered into a definitive agreement to be acquired by Merck KGaA at an equity value of approximately $1.3B, or $20.00 per ADS. The transaction is expected to close in Q1 2027, subject to shareholder, Court and regulatory approvals.